Streetwise Reports' Article Archives — September 2020 back to current month (29)

Coverage Initiated on Telemedicine Firm in 'Strong Position for Long-Term Growth' (09/30/2020)

The investment thesis for CloudMD Software & Services is presented in a Mackie Research Capital Corp. report.


Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial (09/30/2020)

Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19.


Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial (09/30/2020)

Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin.


Genetron Receives FDA Breakthrough Approval for Hepatocellular Carcinoma Detection Device (09/30/2020)

Genetron Holdings Ltd. shares traded 25% higher after the company reported it has received Breakthrough Device Designation from the FDA for its blood-based next-generation sequencing test for early hepatocellular carcinoma detection.


Aptorum Shares Skyrocket Upon Launching Infectious Disease Liquid Biopsy Unit (09/29/2020)

Shares of Aptorum Group Ltd. traded nearly 300% higher after the company reported it launched an infectious disease liquid biopsy start-up subsidiary.


GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test (09/28/2020)

GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test.


Owens & Minor Shares Climb 50% after Raising FY/20 Earnings Guidance by 66% (09/24/2020)

Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021.


Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study (09/23/2020)

Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2.


California-Based Biotech Receives COVID-19 Trial Clearance (09/23/2020)

The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report.


Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens (09/23/2020)

ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies.


AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study (09/22/2020)

AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands.


FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients (09/21/2020)

Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress.


Biopharma Advances Development of Psilocybin-Based Therapeutics (09/21/2020)

Revive Therapeutics provides an update on its psychedelics therapeutics programs.


Pharma Greenlighted to Continue Multinational COVID-19 Study (09/18/2020)

This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial.


Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19 (09/17/2020)

Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data.


Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial (09/17/2020)

Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients.


Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug (09/16/2020)

The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report.


Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial (09/16/2020)

Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease.


Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results (09/15/2020)

Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy.


Amwell, with $100 Million Google Investment and Access to 80 Million Patients, Expected to Begin Trading on NYSE Sept. 17 (09/15/2020)

Virtual care company American Well Corp., which operates under the name Amwell®, is expected to begin trading on the New York Stock Exchange on Thursday, September 17, under the symbol AMWL.


Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer (09/14/2020)

Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash.


As COVID Is Turbocharging the Adoption of TeleHealth, Small Cap Is Growing Exponentially (09/09/2020)

All three brokerage firms that cover the rapidly expanding CloudMD Software & Services rate the company a Speculative Buy, and now the company has gained a toehold in the U.S.


Life Sciences Company Posts Record Q3 Revenue Due to Successful Recurring Purchase Model (09/09/2020)

Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels.


Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings (09/09/2020)

Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy.


U.S. Medical Device Firm to Acquire Developer of Dissection Stent (09/09/2020)

The specifics of the deal and the next steps for CryoLife are presented in a Ladenburg Thalmann report.


Trillium Shares Get Boost from Dose Escalation Trial Data and Pfizer's $25 Million Equity Investment (09/09/2020)

Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc.


Biopharma Achieves 'Big Phase 3 Win' for its Pediatric Intrahepatic Cholestasis Drug (09/09/2020)

The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report.


Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder (09/04/2020)

Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder.


Life Sciences Firm Gains Protocol Approval for Phase 3 COVID-19 Study (09/02/2020)

Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19.


More Archives

2024Jun May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes